



US009820691B2

(12) **United States Patent**
Kiani

(10) **Patent No.:** **US 9,820,691 B2**
(45) **Date of Patent:** ***Nov. 21, 2017**

(54) **FLUID TITRATION SYSTEM**

(75) Inventor: **Massi E. Kiani**, Laguna Niguel, CA (US)

(73) Assignee: **MASIMO CORPORATION**, Irvine, CA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 322 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **13/287,060**

(22) Filed: **Nov. 1, 2011**

(65) **Prior Publication Data**

US 2012/0046557 A1 Feb. 23, 2012

Related U.S. Application Data

(63) Continuation of application No. 12/208,998, filed on Sep. 11, 2008, now Pat. No. 8,048,040.

(60) Provisional application No. 60/993,584, filed on Sep. 13, 2007.

(51) **Int. Cl.**

A61B 5/00 (2006.01)

A61B 5/0295 (2006.01)

A61B 5/1455 (2006.01)

A61M 5/142 (2006.01)

(52) **U.S. Cl.**

CPC **A61B 5/6826** (2013.01); **A61B 5/0295** (2013.01); **A61B 5/14551** (2013.01); **A61B 5/6838** (2013.01); **A61M 5/142** (2013.01); **A61M 2205/3306** (2013.01); **A61M 2205/3313** (2013.01)

(58) **Field of Classification Search**

CPC .. A61M 2205/3306; A61M 2205/3313; A61M 5/142; A61B 5/14551; A61B 5/6826; A61B 5/6838; A61B 5/0295; A61B 5/0806

USPC 604/65-67, 503

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,109,643 A 8/1978 Bond et al.
4,960,128 A 10/1990 Gordon et al.
4,964,408 A 10/1990 Hink et al.
5,041,187 A 8/1991 Hink et al.
5,069,213 A 12/1991 Polczynski
5,111,817 A 5/1992 Clark et al.
5,163,438 A 11/1992 Gordon et al.
5,337,744 A 8/1994 Branigan

(Continued)

Primary Examiner — Bhisma Mehta


Assistant Examiner — Larry R Wilson

(74) *Attorney, Agent, or Firm* — Knobbe, Martens, Olson & Bear LLP

(57) **ABSTRACT**

A fluid titration system has an optical sensor, a physiological monitor, a titration controller and an infusion device. The optical sensor transmits multiple wavelengths of light into a tissue site of a person and detects the optical radiation after attenuation by pulsatile blood flowing within the tissue site. The physiological monitor receives a resulting sensor signal and derives a plethysmograph that corresponds to the pulsatile blood flow. The monitor also calculates a plethysmograph variability measure that is responsive to changes in perfusion at the tissue site. A titration controller generates a fluid control output according to the variability measure. The infusion device administers a liquid solution via an intravenous (IV) connection to the person according to the fluid control output so as to regulate at least one of a fluid flow start, rate and stop.

20 Claims, 8 Drawing Sheets



(56)

References Cited

U.S. PATENT DOCUMENTS

5,341,805 A	8/1994	Stavridi et al.	6,241,683 B1	6/2001	Macklem et al.
D353,195 S	12/1994	Savage et al.	6,253,097 B1	6/2001	Aronow et al.
D353,196 S	12/1994	Savage et al.	6,256,523 B1	7/2001	Diab et al.
5,377,676 A	1/1995	Vari et al.	6,263,222 B1	7/2001	Diab et al.
D359,546 S	6/1995	Savage et al.	6,278,522 B1	8/2001	Lepper, Jr. et al.
5,431,170 A	7/1995	Mathews	6,280,213 B1	8/2001	Tobler et al.
D361,840 S	8/1995	Savage et al.	6,285,896 B1	9/2001	Tobler et al.
D362,063 S	9/1995	Savage et al.	6,301,493 B1	10/2001	Marro et al.
5,452,717 A	9/1995	Branigan et al.	6,317,627 B1	11/2001	Ennen et al.
D363,120 S	10/1995	Savage et al.	6,321,100 B1	11/2001	Parker
5,456,252 A	10/1995	Vari et al.	6,325,761 B1	12/2001	Jay
5,479,934 A	1/1996	Imran	6,334,065 B1	12/2001	Al-Ali et al.
5,482,036 A	1/1996	Diab et al.	6,343,224 B1	1/2002	Parker
5,490,505 A	2/1996	Diab et al.	6,349,228 B1	2/2002	Kiani et al.
5,494,043 A	2/1996	O'Sullivan et al.	6,360,114 B1	3/2002	Diab et al.
5,533,511 A	7/1996	Kaspari et al.	6,368,283 B1	4/2002	Xu et al.
5,534,851 A	7/1996	Russek	6,371,921 B1	4/2002	Caro et al.
5,561,275 A	10/1996	Savage et al.	6,377,829 B1	4/2002	Al-Ali
5,562,002 A	10/1996	Lalin	6,388,240 B2	5/2002	Schulz et al.
5,590,649 A	1/1997	Caro et al.	6,397,091 B2	5/2002	Diab et al.
5,602,924 A	2/1997	Durand et al.	6,430,437 B1	8/2002	Marro
5,632,272 A	5/1997	Diab et al.	6,430,525 B1	8/2002	Weber et al.
5,638,816 A	6/1997	Kiani-Azarbayjany et al.	6,463,311 B1	10/2002	Diab
5,638,818 A	6/1997	Diab et al.	6,470,199 B1	10/2002	Kopotic et al.
5,645,440 A	7/1997	Tobler et al.	6,501,975 B2	12/2002	Diab et al.
5,685,299 A	11/1997	Diab et al.	6,505,059 B1	1/2003	Kollias et al.
D393,830 S	4/1998	Tobler et al.	6,515,273 B2	2/2003	Al-Ali
5,743,262 A	4/1998	Lepper, Jr. et al.	6,519,487 B1	2/2003	Parker
5,758,644 A	6/1998	Diab et al.	6,525,386 B1	2/2003	Mills et al.
5,760,910 A	6/1998	Lepper, Jr. et al.	6,526,300 B1	2/2003	Kiani et al.
5,766,127 A	6/1998	Pologe et al.	6,541,756 B2	4/2003	Schulz et al.
5,769,785 A	6/1998	Diab et al.	6,542,764 B1	4/2003	Al-Ali et al.
5,782,757 A	7/1998	Diab et al.	6,580,086 B1	6/2003	Schulz et al.
5,785,659 A	7/1998	Caro et al.	6,584,336 B1	6/2003	Ali et al.
5,791,347 A	8/1998	Flaherty et al.	6,595,316 B2	7/2003	Cybulski et al.
5,810,734 A	9/1998	Caro et al.	6,597,932 B2	7/2003	Tian et al.
5,823,950 A	10/1998	Diab et al.	6,597,933 B2	7/2003	Kiani et al.
5,830,131 A	11/1998	Caro et al.	6,606,511 B1	8/2003	Ali et al.
5,833,618 A	11/1998	Caro et al.	6,632,181 B2	10/2003	Flaherty et al.
5,860,919 A	1/1999	Kiani-Azarbayjany et al.	6,639,668 B1	10/2003	Trepagnier
5,862,805 A *	1/1999	Nitzan A61B 5/02416	6,640,116 B2	10/2003	Diab
		128/898	6,643,530 B2	11/2003	Diab et al.
5,890,929 A	4/1999	Mills et al.	6,650,917 B2	11/2003	Diab et al.
5,904,654 A	5/1999	Wohltmann et al.	6,654,624 B2	11/2003	Diab et al.
5,919,134 A	7/1999	Diab	6,658,276 B2	12/2003	Kianl et al.
5,934,925 A	8/1999	Tobler et al.	6,661,161 B1	12/2003	Lanzo et al.
5,940,182 A	8/1999	Lepper, Jr. et al.	6,671,531 B2	12/2003	Al-Ali et al.
5,984,893 A *	11/1999	Ward A61M 5/16827	6,678,543 B2	1/2004	Diab et al.
		128/DIG. 12	6,684,090 B2	1/2004	Ali et al.
5,995,855 A	11/1999	Kiani et al.	6,684,091 B2	1/2004	Parker
5,997,343 A	12/1999	Mills et al.	6,697,656 B1	2/2004	Al-Ali
6,002,952 A	12/1999	Diab et al.	6,697,657 B1	2/2004	Shehada et al.
6,011,986 A	1/2000	Diab et al.	6,697,658 B2	2/2004	Al-Ali
6,027,452 A	2/2000	Flaherty et al.	RE38,476 E	3/2004	Diab et al.
6,036,642 A	3/2000	Diab et al.	6,699,194 B1	3/2004	Diab et al.
6,045,509 A	4/2000	Caro et al.	6,714,804 B2	3/2004	Al-Ali et al.
6,067,462 A	5/2000	Diab et al.	RE38,492 E	4/2004	Diab et al.
6,081,735 A	6/2000	Diab et al.	6,721,582 B2	4/2004	Trepagnier et al.
6,088,607 A	7/2000	Diab et al.	6,721,585 B1	4/2004	Parker
6,110,522 A	8/2000	Lepper, Jr. et al.	6,725,075 B2	4/2004	Al-Ali
6,124,597 A	9/2000	Shehada	6,728,560 B2	4/2004	Kollias et al.
6,128,521 A	10/2000	Marro et al.	6,735,459 B2	5/2004	Parker
6,129,675 A	10/2000	Jay	6,745,060 B2	6/2004	Diab et al.
6,144,868 A	11/2000	Parker	6,760,607 B2	7/2004	Al-Ali
6,151,516 A	11/2000	Kiani-Azarbayjany et al.	6,770,028 B1	8/2004	Ali et al.
6,152,754 A	11/2000	Gerhardt et al.	6,771,994 B2	8/2004	Kiani et al.
6,157,850 A	12/2000	Diab et al.	6,792,300 B1	9/2004	Diab et al.
6,165,005 A	12/2000	Mills et al.	6,813,511 B2	11/2004	Diab et al.
6,165,151 A *	12/2000	Weiner A61M 5/16813	6,816,741 B2	11/2004	Diab
		604/250	6,822,564 B2	11/2004	Al-Ali
6,184,521 B1	2/2001	Coffin, IV et al.	6,826,419 B2	11/2004	Diab et al.
6,206,830 B1	3/2001	Diab et al.	6,830,711 B2	12/2004	Mills et al.
6,229,856 B1	5/2001	Diab et al.	6,850,787 B2	2/2005	Weber et al.
6,232,609 B1	5/2001	Snyder et al.	6,850,788 B2	2/2005	Al-Ali
6,236,872 B1	5/2001	Diab et al.	6,852,083 B2	2/2005	Caro et al.
			6,861,639 B2	3/2005	Al-Ali
			6,898,452 B2	5/2005	Al-Ali et al.
			6,920,345 B2	7/2005	Al-Ali et al.
			6,931,268 B1	8/2005	Kiani-Azarbayjany et al.

(56)

References Cited

U.S. PATENT DOCUMENTS

6,934,570 B2	8/2005	Kiani et al.	7,496,391 B2	2/2009	Diab et al.
6,939,305 B2	9/2005	Flaherty et al.	7,496,393 B2	2/2009	Diab et al.
6,943,348 B1	9/2005	Coffin, IV	D587,657 S	3/2009	Al-Ali et al.
6,950,687 B2	9/2005	Al-Ali	7,499,741 B2	3/2009	Diab et al.
6,961,598 B2	11/2005	Diab	7,499,835 B2	3/2009	Weber et al.
6,970,792 B1	11/2005	Diab	7,500,950 B2	3/2009	Al-Ali et al.
6,979,812 B2	12/2005	Al-Ali	7,509,154 B2	3/2009	Diab et al.
6,985,764 B2	1/2006	Mason et al.	7,509,494 B2	3/2009	Al-Ali
6,993,371 B2	1/2006	Kiani et al.	7,510,849 B2	3/2009	Schurman et al.
6,996,427 B2	2/2006	Ali et al.	7,526,328 B2	4/2009	Diab et al.
6,999,904 B2	2/2006	Weber et al.	7,530,942 B1	5/2009	Diab
7,003,338 B2	2/2006	Weber et al.	7,530,949 B2	5/2009	Al Ali et al.
7,003,339 B2	2/2006	Diab et al.	7,530,955 B2	5/2009	Diab et al.
7,015,451 B2	3/2006	Dalke et al.	7,563,110 B2	7/2009	Al-Ali et al.
7,024,233 B2	4/2006	Ali et al.	7,596,398 B2	9/2009	Al-Ali et al.
7,027,849 B2	4/2006	Al-Ali	7,618,375 B2	11/2009	Flaherty
7,030,749 B2	4/2006	Al-Ali	D606,659 S	12/2009	Kiani et al.
7,039,449 B2	5/2006	Al-Ali	7,647,083 B2	1/2010	Al-Ali et al.
7,041,060 B2	5/2006	Flaherty et al.	D609,193 S	2/2010	Al-Ali et al.
7,044,918 B2	5/2006	Diab	D614,305 S	4/2010	Al-Ali et al.
7,067,893 B2	6/2006	Mills et al.	RE41,317 E	5/2010	Parker
7,096,052 B2	8/2006	Mason et al.	7,729,733 B2	6/2010	Al-Ali et al.
7,096,054 B2	8/2006	Abdul-Hafiz et al.	7,734,320 B2	6/2010	Al-Ali
7,132,641 B2	11/2006	Schulz et al.	7,761,127 B2	7/2010	Al-Ali et al.
7,142,901 B2	11/2006	Kiani et al.	7,761,128 B2	7/2010	Al-Ali et al.
7,149,561 B2	12/2006	Diab	7,764,982 B2	7/2010	Dalke et al.
7,186,966 B2	3/2007	Al-Ali	D621,516 S	8/2010	Kiani et al.
7,190,261 B2	3/2007	Al-Ali	7,791,155 B2	9/2010	Diab
7,201,734 B2	4/2007	Hickle	7,801,581 B2	9/2010	Diab
7,215,984 B2	5/2007	Diab	7,822,452 B2	10/2010	Schurman et al.
7,215,986 B2	5/2007	Diab	RE41,912 E	11/2010	Parker
7,221,971 B2	5/2007	Diab	7,844,313 B2	11/2010	Kiani et al.
7,225,006 B2	5/2007	Al-Ali et al.	7,844,314 B2	11/2010	Al-Ali
7,225,007 B2	5/2007	Al-Ali	7,844,315 B2	11/2010	Al-Ali
RE39,672 E	6/2007	Shehada et al.	7,865,222 B2	1/2011	Weber et al.
7,239,905 B2	7/2007	Kiani-Azarbayjany et al.	7,873,497 B2	1/2011	Weber et al.
7,245,953 B1	7/2007	Parker	7,880,606 B2	2/2011	Al-Ali
7,254,429 B2	8/2007	Schurman et al.	7,880,626 B2	2/2011	Al-Ali et al.
7,254,431 B2	8/2007	Al-Ali	7,891,355 B2	2/2011	Al-Ali et al.
7,254,433 B2	8/2007	Diab et al.	7,894,868 B2	2/2011	Al-Ali et al.
7,254,434 B2	8/2007	Schulz et al.	7,899,507 B2	3/2011	Al-Ali et al.
7,272,425 B2	9/2007	Al-Ali	7,899,518 B2	3/2011	Trepagnier et al.
7,274,955 B2	9/2007	Kiani et al.	7,904,132 B2	3/2011	Weber et al.
D554,263 S	10/2007	Al-Ali	7,909,772 B2	3/2011	Popov et al.
7,280,858 B2	10/2007	Al-Ali et al.	7,910,875 B2	3/2011	Al-Ali
7,289,835 B2	10/2007	Mansfield et al.	7,919,713 B2	4/2011	Al-Ali et al.
7,292,883 B2	11/2007	De Felice et al.	7,937,128 B2	5/2011	Al-Ali
7,295,866 B2	11/2007	Al-Ali	7,937,129 B2	5/2011	Mason et al.
7,328,053 B1	2/2008	Diab et al.	7,937,130 B2	5/2011	Diab et al.
7,332,784 B2	2/2008	Mills et al.	7,941,199 B2	5/2011	Kiani
7,340,287 B2	3/2008	Mason et al.	7,951,086 B2	5/2011	Flaherty et al.
7,341,559 B2	3/2008	Schulz et al.	7,957,780 B2	6/2011	Lamego et al.
7,343,186 B2	3/2008	Lamego et al.	7,962,188 B2	6/2011	Kiani et al.
D566,282 S	4/2008	Al-Ali et al.	7,962,190 B1	6/2011	Diab et al.
7,355,512 B1	4/2008	Al-Ali	7,976,472 B2	7/2011	Kiani
7,356,365 B2	4/2008	Schurman	7,988,637 B2	8/2011	Diab
7,371,981 B2	5/2008	Abdul-Hafiz	7,990,382 B2	8/2011	Kiani
7,373,193 B2	5/2008	Al-Ali et al.	7,991,446 B2	8/2011	Ali et al.
7,373,194 B2	5/2008	Weber et al.	8,000,761 B2	8/2011	Al-Ali
7,376,453 B1	5/2008	Diab et al.	8,008,088 B2	8/2011	Bellott et al.
7,377,794 B2	5/2008	Al-Ali et al.	RE42,753 E	9/2011	Kiani-Azarbayjany et al.
7,377,899 B2	5/2008	Weber et al.	8,019,400 B2	9/2011	Diab et al.
7,383,070 B2	6/2008	Diab et al.	8,028,701 B2	10/2011	Al-Ali et al.
7,415,297 B2	8/2008	Al-Ali et al.	8,029,765 B2	10/2011	Bellott et al.
7,428,432 B2	9/2008	Ali et al.	8,036,728 B2	10/2011	Diab et al.
7,438,683 B2	10/2008	Al-Ali et al.	8,046,040 B2	10/2011	Ali et al.
7,440,787 B2	10/2008	Diab	8,046,041 B2	10/2011	Diab et al.
7,454,240 B2	11/2008	Diab et al.	8,046,042 B2	10/2011	Diab et al.
7,467,002 B2	12/2008	Weber et al.	8,048,040 B2	11/2011	Kiani
7,469,157 B2	12/2008	Diab et al.	8,050,728 B2	11/2011	Al-Ali et al.
7,471,969 B2	12/2008	Diab et al.	2005/0177096 A1	8/2005	Bollich et al.
7,471,971 B2	12/2008	Diab et al.	2007/0032732 A1 *	2/2007	Shelley A61B 5/0059
7,483,729 B2	1/2009	Al-Ali et al.			600/504
7,483,730 B2	1/2009	Diab et al.	2007/0055198 A1 *	3/2007	O'Mahony A61M 5/14212
7,489,958 B2	2/2009	Diab et al.			604/67
			2008/0067132 A1 *	3/2008	Ross A61B 5/02007
					210/739

* cited by examiner




FIG. 1 (Prior Art)




FIG. 2 (Prior Art)




FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG. 7




FIG. 8

FLUID TITRATION SYSTEM

REFERENCE TO RELATED APPLICATION

The present application claims priority benefit under 35 U.S.C. §120 to, and is a continuation of U.S. patent application Ser. No. 12/208,998, filed on Sep. 11, 2008, entitled "Fluid Titration System," now U.S. Pat. No. 8,048,040, which claims priority benefit under 35 U.S.C. §119 (e) from U.S. Provisional application No. 60/993,584, filed Sep. 13, 2007, entitled "Fluid Titration System," which is incorporated herein by reference.

BACKGROUND OF THE INVENTION

FIG. 1 illustrates a physiological monitoring system 100 having a physiological monitor 120, a noninvasive sensor 130 attached to a tissue site 1, and a sensor cable 140 interconnecting the monitor 120 and the sensor 130. Physiological monitoring systems for measuring constituents of circulating blood have gained rapid acceptance in a wide variety of medical applications, including surgical wards, intensive care and neonatal units, general wards, home care, physical training, and virtually all types of monitoring scenarios. The noninvasive sensor 130 has light emitting diodes (LEDs) and a detector. The LEDs transmit optical radiation into the tissue site 1, and the detector responds to the intensity of the optical radiation after absorption by pulsatile blood flow within the tissue site. Based upon this response, the physiological monitor 120 determines measurements for physiological parameters. The physiological monitoring system 100 may incorporate pulse oximetry, which is a widely accepted noninvasive procedure for measuring physiological parameters, such as oxygen saturation and pulse rate among others. The physiological monitoring system 100 may also incorporate advanced features, such as a multiple wavelength sensor and advanced processes for determining other physiological parameters, such as carboxyhemoglobin, methemoglobin and total hemoglobin, as a few examples. The physiological monitor 120 displays the physiological parameters and typically provides visual and audible alarm mechanisms that alert a caregiver when these parameters are outside of predetermined limits.

Pulse oximeters capable of reading through motion induced noise are disclosed in at least U.S. Pat. Nos. 6,770,028, 6,658,276, 6,650,917, 6,157,850, 6,002,952, 5,769,785, and 5,758,644; low noise pulse oximetry sensors are disclosed in at least U.S. Pat. No. 6,088,607 and 5,782,757; all of which are assigned to Masimo Corporation, Irvine, Calif. ("Masimo") and are incorporated by reference herein.

Physiological monitors and corresponding multiple wavelength optical sensors are described in at least U.S. patent application Ser. No. 11/367,013, filed Mar. 1, 2006 and entitled Multiple Wavelength Sensor Emitters and U.S. patent application Ser. No. 11/366,208 [11,367,033], filed Mar. 1, 2006 and entitled Noninvasive Multi-Parameter Patient Monitor, both assigned to Masimo Laboratories, Irvine, Calif. (Masimo Labs) and both incorporated by reference herein.

Further, physiological monitoring systems that include low noise optical sensors and pulse oximetry monitors, such as any of LNOP® adhesive or reusable sensors, SofTouch™ sensors, Hi-Fi Trauma™ or Blue™ sensors; and any of Radical®, SatShare™, Rad-9™, Rad-5™, Rad-5v™ or PPO+™ Masimo SET® pulse oximeters, are all available from Masimo. Physiological monitoring systems including

multiple wavelength sensors and corresponding noninvasive blood parameter monitors, such as Rainbow™ adhesive and reusable sensors and RAD-57™ and Radical-7™ monitors for measuring SpO₂, pulse rate, perfusion index, signal quality, HbCO and HbMet among other parameters are also available from Masimo.

FIG. 2 illustrates the standard plethysmograph waveform 200, which can be derived from a pulse oximetry system, as described above. The plethysmograph waveform 200 illustrates light absorption at the tissue site, shown along the y-axis 10, versus time, shown along the x-axis 20. The total absorption includes components of static absorption 210 and variable absorption 220. Static absorption 210 is due to tissue, venous blood and a base volume of arterial blood. Variable absorption 220 is due to the pulse-added volume of arterial blood. That is, the plethysmograph waveform 200 is a visualization of the tissue site arterial blood volume change over time, and is a function of heart stroke volume, pressure gradient, arterial elasticity and peripheral resistance. The ideal waveform pulse 230 displays a broad peripheral flow curve, with a short, steep inflow phase 232 followed by a 3 to 4 times longer outflow phase 234. The inflow phase 232 is the result of tissue distention by the rapid blood volume inflow during ventricular systole. During the outflow phase 234, blood flow continues into the vascular bed during diastole. The plethysmograph baseline 240 indicates the minimum basal tissue perfusion.

SUMMARY OF THE INVENTION

FIG. 3 illustrates a hypovolemic plethysmograph waveform 300, i.e. a plethysmograph displaying characteristics of a person having an abnormal decrease in blood volume. Hypovolemia is often caused from blood loss during surgery or due to an injury. Under hypovolemic conditions, a respiration-induced cyclical variation occurs in a plethysmograph baseline 340. In particular, the baseline 340 varies with a period corresponding to the respiration rate 350. This cyclical variation is particularly evident in patients undergoing positive ventilation. The amount of cyclical variation correlates to a person's blood volume, i.e. the less blood volume the greater the cyclical variation in the plethysmograph waveform. Accordingly, a measure of plethysmograph variation may be indicative of hypovolemic conditions.

FIG. 4 illustrates a plethysmograph 400 plotted on an amplitude axis 30 versus a time axis 40. As described above, the amplitude may be responsive to light absorption of pulsatile blood flow with a person's tissue. The plethysmograph 400 has multiple pulses 460 each with a peak 462 and a valley 464 and extending over a time period 466. A perfusion index (PI) value can be defined for each pulse 460:

$$PI = AC/DC \quad (1)$$

where "AC" 454 designates a peak amplitude 462 minus a valley amplitude 464 for a particular pulse and where "DC" 456 designates a peak amplitude 462 for a particular pulse. In an embodiment, an IR channel plethysmograph from a detector response to an IR wavelength LED is utilized to calculate PI. A plethysmograph variability index (PVI) is then calculated that is responsive to variations in perfusion index, as described below.

In an embodiment, PVI calculations utilize only PI values resulting from acceptable plethysmograph pulses. For example, a red channel plethysmograph responsive to a red wavelength LED is used to verify acceptable pulses in the IR channel. Physiological plethysmograph identification is disclosed in U.S. Pat. No. 7,044,918 titled Plethysmograph

Pulse Recognition Processor, which is incorporated by reference herein. PVI values are calculated from a sorted and trimmed buffer representing a sliding time window of PI values. The sort orders the PI values from the minimum PI at one end of the buffer to the maximum PI at the other end of the buffer. A predetermined number of both maximum and minimum PIs are deleted from each end of the buffer and PVI is calculated as:

$$PVI = [(PI_{MAX} - PI_{MIN}) / PI_{MAX}] \times 100 \quad (2)$$

That is, PVI is the PI variation, expressed as a percentage of the difference between the maximum and minimum PIs remaining in the buffer. In an embodiment, a median PVI is calculated from PVIs stored in a second buffer. PVI is described in U.S. Provisional patent application No. 60/873,663 filed Dec. 09, 2006 titled Plethysmograph Variability Index, incorporated by reference herein. A PVI enabled physiological monitor advantageously provides a noninvasive numerical measure of hypovolemic conditions so as to titrate patient fluids.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is an illustration of a physiological monitoring system;

FIG. 2 is an absorption versus time graph of a standard pulse oximeter plethysmograph;

FIG. 3 is an absorption versus time graph of a plethysmograph exhibiting a respiration-induced, baseline cyclical variation;

FIG. 4 is a plethysmograph illustrating measurement of a plethysmograph variability index (PVI);

FIG. 5 is a general block diagram of an intravenous fluid titration system;

FIG. 6 is a general block diagram of a physiological monitoring system configured for a fluid titration application; and

FIGS. 7-8 are illustrations of intravenous fluid titration system embodiments.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

FIG. 5 illustrates a fluid titration system 500 having a sensor 510 attached to a person 2, a physiological monitor 520, a fluid titration controller 530 and an intravenous (IV) infusion device 540. Advantageously, the fluid titration system 500 utilizes a perfusion variability parameter, such as PVI described above, to regulate the administration of fluids to a person so as to control or prevent low blood volume or a hypovolemia. A noninvasive, optical sensor 510 allows a measure of tissue blood perfusion by detecting the absorption of sensor transmitted light by pulsatile blood flow within a tissue site, such as a finger, foot or ear to name a few. A sensor signal 512 responsive to that absorption is received and processed by the physiological monitor 520, which derives a plethysmograph variability index (PVI) or other measure of plethysmograph variability or, similarly, blood perfusion variability. A fluid titration controller 530 is responsive to PVI 522 and in particular to relatively large values of PVI indicating relatively large variations in perfusion index, a potential indicator of hypovolemia. The fluid titration controller 530, in turn, provides a control output 532 to an intravenous (IV) infusion device 540 so as to regulate circulating fluids and alleviate a hypovolemic condition in the person 2. The IV infusion device 540 administers a liquid solution, such as blood products or nutrient

fluids injected directly into a vein (usually in the arm) at a prescribed rate over a period of time. In a closed-loop embodiment, the fluid titration controller 530 is responsive to PVI 522 or similar measure so as to start, control the rate of, or stop the infusion of fluids into the person 2. In an open-loop embodiment, the fluid titration controller 530 presents a display or other indicator 534 to a care provider 3 who manually inputs an adjustment or other setting 541 into the infusion device 540 so as to start, control the rate of, or stop the infusion of fluids into the person 2.

As shown in FIG. 5, the fluid titration controller 530 may be implemented in the physiological monitor 520, implemented in the IV infusion device 540, distributed between the physiological monitor 520 and the IV infusion device 540, or implemented as a standalone processing device. In an embodiment, the fluid titration controller 530 is a firmware process executed within the physiological monitor 520, as described with respect to FIG. 6, below. Physically, the physiological monitor 520 and the IV infusion device 540 may be separate units, as described with respect to FIG. 7, below, or combined into a single unit, as described with respect to FIG. 8, below.

FIG. 6 illustrates a physiological monitoring system 600 capable of generating one or more blood parameter measurements such as oxygen saturation, perfusion index, carboxyhemoglobin and methemoglobin, to name a few. The monitoring system 600 has a sensor 510 and a physiological monitor 520. The sensor 510 attaches to a tissue site 1 and includes a plurality of emitters 610 capable of irradiating the tissue site 1 with various wavelengths of light, such as the red and infrared (IR) wavelengths utilized in pulse oximetry or multiple wavelengths different than or in addition to pulse oximetry wavelengths such as for measuring abnormal hemoglobin constituents. The sensor 510 also includes one or more detectors 612 capable of detecting the emitted light after attenuation by the tissue site 1.

As shown in FIG. 6, the physiological monitor 520 communicates with the sensor 510 to receive one or more intensity signals 614 responsive to one or more physiological parameters, then calculates and displays the parameter values. The physiological monitor 520 has drivers 620 that convert digital control signals into analog drive signals capable of driving the emitters 610. A front-end 630 converts composite analog intensity signal(s) 614 from the detector(s) 612 into digital data 632 input to a digital signal processor (DSP) 640. The input digital data 632 is referred to herein as a plethysmograph waveform or a "plethysmograph" for short. In an embodiment, the input digital data 632 is a multiplexed data stream including a red channel plethysmograph and an IR channel plethysmograph generated from alternate activation of red and IR wavelength emitters 610. The DSP 640 may comprise a wide variety of data and/or signal processors capable of executing processes in one or more of hardware, software and firmware for determining physiological parameters from the input data 632. In an embodiment, the DSP 640 generates PVI measurements 642 responsive to an IR channel plethysmograph portion of the digital data 632.

Also shown in FIG. 6, a fluid titration process, such as firmware executing on the DSP, inputs the PVI measurements 642 and generates control values 644 that are communicated directly or indirectly to an IV infusion device 540 (FIG. 5) so as to start, stop, continue or modify the infusion of fluids into a person 2 (FIG. 5). In an embodiment, the fluid titration process 670 is closed-loop and control values 644 are communicated to an IV infusion device 540 (FIG. 5) without human intervention. In an embodiment, the fluid

5

titration process 670 is open-loop and control values 644 are communicated to a care provider 3 (FIG. 5) via a display 662, audible indicator 664 or other human interface device so that the care provider can manually adjust or provide settings for the IV infusion device 540 (FIG. 5) so as to regulate fluid infusion into the person 2 (FIG. 5).

Also shown in FIG. 6, the instrument manager 650 may comprise one or more microcontrollers controlling system management, such as monitoring the activity of the DSP 640 and communicating with I/O devices 660. In an embodiment, I/O devices 660 include one or more of a display 662, an audible indicator 664, a user input 666 and a device interface 688. A display 662 includes for example a readout, colored light or graphic generated by one or more of an LED, LCD, plasma screen or CRT, to name a few. An audible indicator 664 includes, for example, one or more of a speaker or other audio transducer. The user input device 666 may include, for example, one or more of a keypad, touch screen, pointing device, voice recognition device, or the like, or a network, computer or similar device that provides an external input capability.

Further shown in FIG. 6, the display 662, the audible indicator 664 or both in combination are capable of conveying information so that a caregiver 3 (FIG. 5) can manually adjust or otherwise provide inputs for a medical instrument, such as an IV infusion device 540 (FIG. 5), according to digital data 632 derived from an optical sensor 510 and processed by the DSP 640, the instrument manager 650 or both. For example, besides displaying indicia representative of calculated physiological parameters such as one or more of a pulse rate (PR), signal quality and values of blood constituents in body tissue, the display 662 is capable of guiding manual adjustment of an IV infusion device, such as by indicating a +, -, "on" and "off" to prompt a manual increase, decrease, stop or start of fluid flow.

In an embodiment, the instrument manager 650 provides a control signal 659 responsive to control values 644 calculated by the fluid titration firmware 670. The control signal 659 communicates with a device interface 668 so as to generate a corresponding IV infusion device control 532. For example, the instrument manager 360 converts PVI measurements 344 to a control signal 644 and transmits the control signal via the control port 659 to a device interface 668.

In an embodiment, an input port 658 responds to a user input device 666, such as a keypad, network, computer or similar device that provides an external interface. Using this interface, a caregiver 3 (FIG. 5) can initialize the instrument manager 650 with patient information, infusion device type and fluid type to name a few. During operation, the instrument manager converts the control values 644 to an appropriate control signal 659 according to the initialization information.

The fluid titration process 670 may be DSP firmware that executes a closed-loop algorithm for controlling an IV infusion device 540 based upon PVI or other measured plethysmograph or perfusion variability parameter. In an embodiment, the fluid titration process 670 triggers a control output 644 so as to disable fluid flow from the IV infusion device 540 if PVI falls below a predetermined threshold or otherwise reflects that hypovolemia may no longer be indicated for a patient 2 (FIG. 5). In an embodiment, the fluid titration process 670 triggers a control output 644 so as to enable fluid flow from the IV infusion device 540 if PVI increases above a predetermined threshold or otherwise reflects that hypovolemia may no longer be indicated for a patient 2 (FIG. 5). In an embodiment, the fluid titration

6

process 670 modifies a control output 644 so as to adjust the rate of fluid flow or total administered amount of fluid flow from the IV infusion device 540 according to changes in PVI that reflect that hypovolemia may be decreasing or increasing in severity.

FIG. 7 illustrates a fluid titration system embodiment 700 having an optical sensor 710 attached to a person 2; a physiological monitor 720; a sensor cable 730 interconnecting the sensor 710 and monitor 720; an IV infusion device 740; a control cable 750 interconnecting the monitor 720 and infusion device 740; and an IV tube 760 also attached to the person 2. The optical sensor 710 provides a sensor signal via a sensor cable 730 to the physiological monitor 720. The physiological monitor 720 generates blood parameter measurements and processes those parameters to generate monitor and control outputs, as described with respect to FIGS. 5-6, above. In particular, the physiological monitor 720 generates control signals via a control cable 750 to the IV infusion device 740, which provides fluids to the person 2 via the IV tube 760.

FIG. 8 illustrates another fluid titration system embodiment 800 having an optical sensor 810 and an IV tube 840 attached to a person 2 at one end and an integrated physiological monitor 820 at another end. The integrated physiological monitor 820 incorporates the functions of a physiological monitor 520 (FIG. 6) and an IV infusion device within a single unit or within physically connected units.

A fluid titration system has been disclosed in detail in connection with various embodiments. These embodiments are disclosed by way of examples only and are not to limit the scope of the claims that follow. One of ordinary skill in art will appreciate many variations and modifications.

What is claimed is:

1. A fluid titration system comprising:

- a noninvasive optical sensor including a light source configured to irradiate tissue of a monitored patient and one or more photodetectors configured to detect said light after attenuation by said tissue, said sensor outputting a signal responsive to said detected attenuated light, said signal including a pulsatile component responsive to variable absorption and a nonpulsatile component responsive to static absorption, said pulsatile component and said nonpulsatile component indicative of a blood volume in said patient;
- a physiological monitor configured to communicate with said sensor and receive said signal, said physiological monitor including a processor configured to process said signal to determine a measure of variability that depends at least on a ratio of said pulsatile component to said nonpulsatile component;
- a fluid titration controller configured to access said measure of variability and to output an infusion trigger when said measure of variability indicates a need for additional liquids by said patient; and
- a stand-alone infusion device configured to administer liquid solutions to said patient upon receipt of said infusion trigger, wherein said physiological monitor also houses said fluid titration controller.

2. The fluid titration system according to claim 1 wherein said fluid titration controller outputs said infusion trigger when said measure of variability indicates a blood volume decrease due to dehydration.

3. The fluid titration system according to claim 1 wherein said fluid titration controller outputs said infusion trigger when said measure of variability indicates a blood volume decrease due to hemorrhaging.

4. The fluid titration system according to claim 1 wherein said fluid titration controller outputs said infusion trigger when said measure of variability indicates a blood volume decrease due to a medical procedure being performed on said patient.

5. The fluid titration system according to claim 1 wherein said liquid solution comprises blood products.

6. The fluid titration system according to claim 1 wherein said liquid solution comprises nutrient fluids.

7. The fluid titration system according to claim 1 wherein said processor is configured to determine said measure of variability from at least a change in the ratio of said pulsatile component to said nonpulsatile component.

8. The fluid titration system according to claim 1 wherein said measure of variability comprises a measure of perfusion index variability.

9. A method of managing a blood volume of a monitored patient, the method comprising:

noninvasively detecting, with a detector of a noninvasive sensor, light attenuated by tissue of said monitored patient at a measurement site;

electronically determining, with a signal processor, a measure of variability depending at least on a ratio of a pulsatile component to a nonpulsatile component of a signal that is responsive to said detected light, said pulsatile component and said nonpulsatile component indicative of a blood volume in said tissue, said pulsatile component responsive to variable absorption and said nonpulsatile component responsive to static absorption;

electronically determining, with said signal processor, whether said measure of variability indicates a need for said monitored patient to receive additional liquid solutions;

electronically triggering a stand-alone infusion device when said determining indicates said need, wherein said triggering comprises generating with an oximeter an infusion device trigger signal; and

administering, with said stand-alone infusion device, liquid solutions when said infusion device is triggered.

10. The method according to claim 9 wherein said administering comprises electronically administering with said infusion device.

11. The method according to claim 9 wherein said electronically determining said measure of variability comprises electronically processing a respiration-induced cyclical variation in said signal.

12. The method according to claim 9 wherein said measure of variability is responsive to a dehydration condition of said patient.

13. The method according to claim 9 wherein said measure of variability is responsive to a hemorrhaging condition of said patient.

14. The method according to claim 9 wherein said electronically determining said measure of variability comprises processing signals responsive to said detected light with said oximeter.

15. The method according to claim 9 wherein said electronically determining whether said measure of variability indicates said need comprises electronically comparing said measure of variability with a predetermined threshold.

16. The method according to claim 9 wherein said electronically determining said measure of variability comprises electronically determining said measure of variability from at least a change in the ratio of said pulsatile component to said nonpulsatile component.

17. The method according to claim 9 wherein said measure of variability comprises a measure of perfusion index variability.

18. A patient monitoring system comprising:

a noninvasive optical sensor including a light source configured to irradiate tissue of a monitored patient and one or more photodetectors configured to detect said light after attenuation by said tissue, said sensor outputting a signal responsive to said detected attenuated light, said signal including a pulsatile component responsive to variable absorption and a nonpulsatile component responsive to static absorption, said pulsatile component and said nonpulsatile component indicative of a blood volume in said patient;

a physiological monitor configured to communicate with said sensor and receive said signal, said physiological monitor including a processor configured to process said signal to determine a measure of variability that depends at least on a ratio of said pulsatile component to said nonpulsatile component; and

a fluid titration controller configured to access said measure of variability and to output an infusion indication when said measure of variability indicates a need for additional liquids by said patient, said infusion indication guiding adjustment of administration of liquid solutions to said patient with a stand-alone infusion device configured to administer said liquid solutions to said patient, wherein said physiological monitor also houses said fluid titration controller.

19. The patient monitoring system according to claim 18 wherein said infusion indication comprises an audible or visual indication and guides manual adjustment of administration of liquid solutions to said patient with said stand-alone infusion device.

20. The patient monitoring system according to claim 18 wherein said fluid titration controller is configured to output said infusion indication to automatically control administration of liquid solutions to said patient with said stand-alone infusion device.

* * * * *

专利名称(译)	流体滴定系统		
公开(公告)号	US9820691	公开(公告)日	2017-11-21
申请号	US13/287060	申请日	2011-11-01
[标]申请(专利权)人(译)	Kiani曾MASSIê		
申请(专利权)人(译)	Kiani曾MASSI E.		
当前申请(专利权)人(译)	Masimo公司		
[标]发明人	KIANI MASSI E		
发明人	KIANI, MASSI E.		
IPC分类号	A61B5/00 A61B5/1455 A61B5/0295 A61M5/142		
CPC分类号	A61B5/6826 A61B5/0295 A61B5/14551 A61M5/142 A61B5/6838 A61M2205/3313 A61M2205/3306		
代理机构(译)	KNOBBE , MARTENS , 奥尔森 & BEAR LLP		
助理审查员(译)	WILSON , LARRY - [R		
优先权	12/208998 2011-11-01 US 60/993584 2007-09-13 US		
其他公开文献	US20120046557A1		
外部链接	Espacenet USPTO		

摘要(译)

流体滴定系统具有光学传感器，生理监测器，滴定控制器和输注装置。光学传感器将多个波长的光传输到人的组织部位，并在通过组织部位内流动的脉动血液衰减后检测光辐射。生理监测器接收所得到的传感器信号并导出对应于脉动血流的体积描记器。监测仪还计算体积描记器变异性测量值，该测量值响应组织部位灌注的变化。滴定控制器根据可变量性测量产生流体控制输出。输液装置根据流体控制输出通过静脉内（IV）连接向人施用液体溶液，以便调节流体流动开始，速率和停止中的至少一个。

